Encouraging Q2 21; but keep a close eye on COVID-19 situation
21/07/21 -"Novartis reported promising Q2 21 results, driven by a combination of improving pandemic situation and ‘softer comps’, i.e. reversal of forward buying in Q2 20. Most importantly, some momentum ..."
Pages
83
Language
English
Published on
21/07/21
You may also be interested by these reports :
30/07/21
Sanofi witnessed remarkable growth in Q2, with strong growth in the high-margin Dupixent and Vaccines business being complemented by the recovery in ...
29/07/21
In its first Litmus test after an ‘ambitious’ CMD in June 2021, the British giant has put up a decent show. The group witnessed recovery in the base ...
29/07/21
Benefiting from the gradual lifting of confinement measures, Ipsen reported a robust sales acceleration in Q2 with the neurosciences and oncology ...
28/07/21
On softer comps, Faes witnessed some recovery in the base business in Q2 21. While resurfacing COVID-19 concerns and Bilastine’s recent patent loss ...